ABVC BioPharma Secures $100,000 Milestone Payment in Vitargus® Licensing Deal with ForSeeCon

ABVC BioPharma has received a $100,000 licensing payment from ForSeeCon Eye Corporation under their global licensing agreement for Vitargus®, bringing total cash payments received to $495,000. The overall licensing structure includes $30 million in equity consideration through 5 million ForSeeCon shares, $3.5 million in total cash payments, and potential royalties up to $60 million based on 5% of net sales, creating a total potential deal value of $63.5 million.

Vitargus® represents a significant advancement in ophthalmic surgery as the world's first biodegradable vitreous substitute designed for retinal detachment procedures. Unlike traditional silicone oil or gas bubble solutions, the product is naturally absorbed and allows patients to maintain upright vision during recovery, eliminating the need for prolonged face-down positioning. According to market research from Verified Market Reports, the global vitreous substitute market was valued at approximately $2.5 billion in 2024 and is projected to reach $4.1 billion by 2033, growing at a 6.3% compound annual growth rate.

The broader retinal surgery devices market, where Vitargus® would compete, presents even greater opportunities. Research from Grand View Research indicates this market was estimated at $2.82 billion in 2024 and is expected to grow to $4.76 billion by 2030, expanding at a 9.2% CAGR. These growth projections highlight the substantial commercial potential for innovative solutions like Vitargus® in addressing retinal disorders.

Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized the strategic importance of this collaboration, noting that the company is positioned to capture both near-term financial benefits and long-term commercial upside through the blended structure of equity, milestone payments, and royalty opportunities. Jerry Chang, CEO of ForSeeCon Eye Corporation, added that the milestone payment reflects confidence in the product's regulatory and commercial trajectory as it generates global interest.

The licensing agreement strengthens ABVC's financial foundation in ophthalmology while providing immediate cash flows and long-term revenue streams. The company's ability to secure such a comprehensive deal demonstrates the perceived value of Vitargus® in addressing the multi-billion-dollar global market for retinal disease treatments, positioning ABVC to potentially deliver transformational shareholder value while advancing innovative ophthalmic solutions.